ARCUS BIOSCIENCES, INC.
Ownership & governance
Executives 5Directors 10Avg age 63Avg tenure 6.8y
TR
Terry Rosen
Chief Executive Officer
Age 67Since 2015-04-30Profile →
+14
Executives5
Board of directors10
TR
Terry Rosen→
Chairman
Age 67Since 2017-11-30
KF
Kathryn Falberg→
Director/Board Member
Age 65Since 2017-09-17
YK
Yasunori Kaneko→
Director/Board Member
Age 71Since 2015-04-30
AR
Antoni Ribas→
Director/Board Member
Age 60Since 2019-10-27
CM
Clarence Machado→
Director/Board Member
Age 62Since 2019-12-09
DL
David Lacey→
Director/Board Member
Age 73Since 2020-05-20
AP
Andrew Perlman→
Director/Board Member
Age 78Since 2020-12-16
NL
Nicole Lambert→
Director/Board Member
Age 52Since 2021-08-02
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| GILEAD SCIENCES, INC. | 24.99 % | 31,424,760 |
| BlackRock Advisors LLC | 10.95 % | 13,778,055 |
| Wellington Trust Co., NA | 4.842 % | 6,089,516 |
| STATE STREET CORPORATION | 4.304 % | 5,412,901 |
| Suvretta Capital Management LLC | 4 % | 5,030,993 |
Catalog · 2026-07-09
Registry officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Jonathan Yingling | Chief Tech/Sci/R&D Officer | 2020-09-30 | - |
| Richard Markus | Chief Tech/Sci/R&D Officer | 2025-01-30 | - |
| Robert Goeltz | Director of Finance/CFO | 2020-07-31 | - |
| Terry Rosen | Chairman | 2017-11-30 | - |
| Terry Rosen | Chief Executive Officer | 2015-04-30 | - |
| Andrew Perlman | Director/Board Member | 2020-12-16 | - |
| Antoni Ribas | Director/Board Member | 2019-10-27 | - |
| Clarence Machado | Director/Board Member | 2019-12-09 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 39.91Range 23–47Analysts 11
23Mean 39.9147
- Buy 11
- Hold 2
Broker actions40 of 104
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Wedbush | Reiterated | Outperform | 43 | 2026-09-30 |
| TD Cowen | Initiated | Buy | — | 2026-09-16 |
| Truist Securities | Reiterated | Buy | 40 | 2026-09-08 |
| Wells Fargo | Maintained | Equal-Weight | 26 | 2026-08-06 |
| Wedbush | Maintained | Outperform | 43 | 2026-08-06 |
| HC Wainwright & Co. | Maintained | Buy | 45 | 2026-07-20 |
| LifeSci Capital | Initiated | Outperform | 46 | 2026-06-04 |
| Morgan Stanley | Maintained | Equal-Weight | 22 | 2026-05-11 |
| Goldman Sachs | Maintained | Buy | 34 | 2026-05-07 |
| Wedbush | Maintained | Outperform | 41 | 2026-04-02 |
| Citigroup | Maintained | Buy | 45 | 2026-03-05 |
| Leerink Partners | Maintained | Outperform | 49 | 2026-03-02 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.